<DOC>
	<DOCNO>NCT02289768</DOCNO>
	<brief_summary>The main purpose vehicle-controlled study determine efficacy safety solution Actikerall® ( contain 5-fluorouracil 0.5 % salicylic acid 10.0 % ) field-directed treatment grade I-II actinic keratosis , apply affected area daily 12 week . A secondary objective study evaluate efficacy Actikerall® solution subclinical actinic keratosis lesion subset patient .</brief_summary>
	<brief_title>Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Salicylic Acid</mesh_term>
	<mesh_term>Salicylates</mesh_term>
	<criteria>Adult male nonpregnant , nonlactating ( last 3 month ) female age 18 85 year ( inclusive ) . Women childbearing potential follow specific study requirement . Patients least 4 10 clinically confirm actinic keratoses lesion grade I II ( accord Olsen EA et al . 1991 ) within field cancerization 25 cm² face/forehead bald scalp . Patients skin type I IV ( accord Fitzpatrick Skin Types ) Patients free significant physical abnormality ( e.g. , tattoo , dermatosis ) potential treatment area may interfere area examination final evaluation . Patients good health condition free medical condition may interfere study result confirm physical examination , medical history laboratory analysis . Patients accept refrain sunbathing , intense UVlight exposure solarium study duration . Patients willing stop use moisturizers topical treatment antiaging product , vitamins A , C , and/or E contain ointment gel green tea preparation treatment area . Patients able ( physical ability supportive person ) apply study preparation correctly follow study procedure restriction . Patients least 3 subclinical lesion 25 cm² test area ( field ) clearly separate actinic keratoses lesion ( additional inclusion criterion patient participate subclinical lesion substudy ) . Subjects receive treatment actinic keratoses within treatment area 3 month previous Visit 1 ( screen ) . Subjects receive prohibited pharmacological nonpharmacological treatment indication actinic keratoses within treatment area randomization ( Visit 2 ) . Subjects receive prohibited systemic treatment indication randomization ( Visit 2 ) . Subjects take phenytoin , methotrexate sulfonylurea . Subjects dermatological disease treatment area surround area may exacerbate study treatment may interfere study assessment ( e.g . psoriasis , eczema ) . Subjects currently malignant benign tumor skin within treatment area ( e.g. , malignant melanoma , basal cell carcinoma , squamous cell carcinoma ) . Subjects suffer kind photodermatoses . Subjects evidence clinically significant unstable medical condition . Subjects know hypersensitivity trial drug ( 5fluorouracil , salicylic acid ) , ingredients trial formulation , drug similar chemical class Subjects allergy dimethylsulfoxide , ethanol , ethyl acetate , pyroxyline , poly ( butyl ) methacrylate , and/or methylmethacrylate . Subjects dihydropyrimidine dehydrogenase deficiency ( DPD deficiency ) . Subjects currently participate participate within 8 week prior Visit 1 another clinical trial . Patients know drug alcohol abuse assess investigator within 2 year prior Visit 1 . Subject institutionalized legal regulatory order .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>